Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab in combination with Carfilzomib/Dexamethasone or Maplirpacept in Relapsed Refractory Multiple Myeloma
NCT05675449Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2022
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of elranatamab in multiple myeloma (MM) (3 arms), sponsored by Pfizer. Primary endpoint: Dose Limiting Toxicity at 64 days. Started Dec 2022; status: active, not recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05675449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675449.